This is a prospective, multicenter, observational study to evaluate the effectiveness of Olmetec® or Olmetec Plus® on nocturnal blood pressure control in Korean patients with stage 1 hypertension. Patients receiving Olmetec-based therapy in routine clinical practice will be followed to assess changes in ambulatory blood pressure, including nocturnal blood pressure and blood pressure variability.
Adults aged ≥19 years
Patients diagnosed with stage 1 hypertension according to clinical guidelines
Patients who are newly prescribed Olmetec® or Olmetec Plus® in routine -clinical practice
Patients who are able to undergo ambulatory blood pressure monitoring (ABPM)
Patients with secondary hypertension
Patients with severe hypertension requiring immediate pharmacological i-ntervention
Patients with known hypersensitivity to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs
Patients who are pregnant, planning to become pregnant, or breastfeeding